4D Molecular Therapeutics, Inc.
FDMT
$14.25
-$0.38-2.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 92.01M | 88.24M | 85.21M | 120.00K | 33.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 92.01M | 88.24M | 85.21M | 120.00K | 33.00K |
| Cost of Revenue | 238.01M | 217.68M | 193.40M | 178.98M | 170.22M |
| Gross Profit | -146.00M | -129.44M | -108.19M | -178.86M | -170.19M |
| SG&A Expenses | 48.82M | 47.81M | 49.06M | 49.32M | 50.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 286.82M | 265.49M | 242.46M | 228.30M | 220.36M |
| Operating Income | -194.82M | -177.25M | -157.25M | -228.18M | -220.33M |
| Income Before Tax | -179.18M | -160.90M | -140.11M | -209.18M | -196.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -179.18 | -160.90 | -140.11 | -209.18 | -196.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -179.18M | -160.90M | -140.11M | -209.18M | -196.14M |
| EBIT | -194.82M | -177.25M | -157.25M | -228.18M | -220.33M |
| EBITDA | -189.79M | -172.33M | -152.55M | -223.61M | -215.82M |
| EPS Basic | -2.76 | -2.70 | -2.55 | -3.74 | -3.52 |
| Normalized Basic EPS | -1.70 | -1.66 | -1.57 | -2.32 | -2.20 |
| EPS Diluted | -2.76 | -2.70 | -2.55 | -3.74 | -3.52 |
| Normalized Diluted EPS | -1.70 | -1.66 | -1.57 | -2.32 | -2.20 |
| Average Basic Shares Outstanding | 258.38M | 244.04M | 231.72M | 223.44M | 222.87M |
| Average Diluted Shares Outstanding | 258.38M | 244.04M | 231.72M | 223.44M | 222.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |